Drug shows promise in overcoming endocrine therapy resistance in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BET inhibitors, a class of drugs already in clinical trials, might work especially well in breast cancer patients who have acquired a Y537S mutation, according to a preclinical study led by researchers at UT Southwestern Medical Center.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login